Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses selecting first- and second-line therapies for patients with advanced bladder cancer and the emerging data and role of immune checkpoint inhibitors.
Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the link between human papillomavirus and oropharyngeal cancers and what is known about the effect of HPV on treatment response and outcome.
Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the evidence for using neoadjuvant and adjuvant systemic therapies in resectable and borderline resectable pancreatic cancer.
Paul M. Cinciripini, PhD, of The University of Texas MD Anderson Cancer Center, discusses the oncologist’s role in addressing and documenting cancer patients’ smoking and cessation attempts as well as treatment advances.
